Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01682876 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 715
- Enrollment target
NCT01682876 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 715 participants.
The verdict
NCT01682876, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 715 participants
- Enrollment target
Study Summary
This study was designed to conduct a comparative trial to further evaluate the safety, immunogenicity and antibody persistence of two doses of Novartis MenACWY conjugate vaccine, given 2 months apart, versus one dose of Novartis MenACWY conjugate vaccine in children 2 through 10 years of age.
Interventions
- BIOLOGICAL MenACWY-CRM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 715 participants |
| Start Date | 2012-10-07 |
| Est. Completion | 2014-05-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01682876
The ClinicalTrials.gov registry entry for NCT01682876 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 715 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MenACWY-CRM is the first listed.
NCT01682876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01682876 about?
NCT01682876 is a clinical study titled "Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.". This study was designed to conduct a comparative trial to further evaluate the safety, immunogenicity and antibody persistence of two doses of Novartis MenACWY conjugate vaccine, given 2 months apart, versus one dose of Novartis MenACWY conjugate vaccine in children 2 through 10 years of age.
What is the current status of trial NCT01682876?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 715 participants. The study started on 2012-10-07. Estimated completion is 2014-05-30.
What interventions are being tested in trial NCT01682876?
The interventions under investigation include: MenACWY-CRM (BIOLOGICAL).
Who is sponsoring clinical trial NCT01682876?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.